- Home
- HBIO vs RLMD Comparison
HBIO vs RLMD Comparison
Compare HBIO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- RLMD
- Stock Information
- Founded
- HBIO 1901
- RLMD 2004
- Country
- HBIO United States
- RLMD United States
- Employees
- HBIO N/A
- RLMD N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- RLMD Health Care
- Exchange
- HBIO Nasdaq
- RLMD Nasdaq
- Market Cap
- HBIO 13.0M
- RLMD 11.5M
- IPO Year
- HBIO 2000
- RLMD N/A
- Fundamental
- Price
- HBIO $0.35
- RLMD $0.39
- Analyst Decision
- HBIO Buy
- RLMD Hold
- Analyst Count
- HBIO 2
- RLMD 4
- Target Price
- HBIO $3.00
- RLMD $4.25
- AVG Volume (30 Days)
- HBIO 1.1M
- RLMD 4.5M
- Earning Date
- HBIO 05-12-2025
- RLMD 05-12-2025
- Dividend Yield
- HBIO N/A
- RLMD N/A
- EPS Growth
- HBIO N/A
- RLMD N/A
- EPS
- HBIO N/A
- RLMD N/A
- Revenue
- HBIO $91,397,000.00
- RLMD N/A
- Revenue This Year
- HBIO N/A
- RLMD N/A
- Revenue Next Year
- HBIO $8.58
- RLMD N/A
- P/E Ratio
- HBIO N/A
- RLMD N/A
- Revenue Growth
- HBIO N/A
- RLMD N/A
- 52 Week Low
- HBIO $0.33
- RLMD $0.24
- 52 Week High
- HBIO $4.08
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- HBIO 43.83
- RLMD 51.73
- Support Level
- HBIO $0.34
- RLMD $0.36
- Resistance Level
- HBIO $0.39
- RLMD $0.44
- Average True Range (ATR)
- HBIO 0.06
- RLMD 0.08
- MACD
- HBIO 0.02
- RLMD -0.00
- Stochastic Oscillator
- HBIO 21.03
- RLMD 26.98
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.